The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Pilipovich A.A.

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Golubev V.L.

Kafedra nervnykh bolezneĭ FPPOV;
GOU VPO "Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova", Moskva

The agonist of dopamine receptors piribedil in treatment of Parkinson’s disease

Authors:

Pilipovich A.A., Golubev V.L.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(6): 83‑90

DOI: 10.17116/jnevro20171176183-90

Read: 3698 times

Download PDF (RU)
Contact the author
Table of contents

THE AGONIST OF DOPAMINE RECEPTORS PIRIBEDIL IN TREATMENT OF PARKINSON’S DISEASE
THE AGONIST OF DOPAMINE RECEPTORS PIRIBEDIL IN TREATMENT OF PARKINSON’S DISEASE

To cite this article:

Pilipovich AA, Golubev VL. The agonist of dopamine receptors piribedil in treatment of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(6):83‑90. (In Russ.)
https://doi.org/10.17116/jnevro20171176183-90

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Art and creativity in Parkinson’s disease: the mysterious effe­cts of dopa­mine. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):13-20
Correlation of motor symptoms and cardiovascular dysfunction in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):59-67
Diagnosis of pathological and adaptive bala­nce changes in Parkinson’s disease to select a reha­bilitation program. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):88-94
Sleep diso­rders in patients with Lewy body deme­ntia and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):81-87
Effect of uric acid on the progression of Parkinson’s disease: Myth or reality?. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):7-14
Change of speech diso­rders during bila­teral deep stimulation of the subthalamic nucleus of the brain in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):59-65
Oxidative stress and depression in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):131-138
Current aspe­cts of the rela­tionship between depression and cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):66-74
Pote­ntial and prospects of the astragaloside IV use for age-associated diseases prevention. Russian Journal of Preventive Medi­cine. 2025;(7):94-99
Dyna­mics of permeability of the blood-brain barrier after FUS thalamotomy acco­rding to contrast-enhanced MRI. Burdenko's Journal of Neurosurgery. 2025;(4):51-60
Abstract:

In this paper, the authors review the current foreign and domestic literature on a role of the agonist of dopamine receptors piribedil in the treatment of Parkinson’s disease. The results of the main studies of the efficacy and safety of piribedil, mechanisms of actions and a comparative characteristics with other dopamine receptors agonist are reviewed.

Keywords:

piribedil
dopamine agonists
Parkinson’s disease
extrapyramidal disorder
piribedil
dopamine agonists
Parkinson’s disease
extrapyramidal disorder

Authors:

Pilipovich A.A.

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Golubev V.L.

Kafedra nervnykh bolezneĭ FPPOV;
GOU VPO "Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova", Moskva

Close metadata

References:

  1. National Institute for Health and Clinical Excellence. Parkinson’s disease: diagnosis and management in primary and secondary care (Internet). London: The Institute; 2006. (cited 2013 Oct 1). (NICE clinical guideline 35). Available from: http://www.nice.org.uk/nicemedia/pdf/cg035niceguideline.pdf. (Referencelist).
  2. Ekstrapiramidnye rasstroistva vchera, segodnya, zavtra. Sb. st. Podred. Levina O.S. 2-e izd. М. 2015. (In Russ.) .
  3. Valdés P, Schneider BL. Gene Therapy: A Promising Approach for Neuroprotection in Parkinson’s Disease? Front Neuroanat. 2016;10;123. https://doi.org/10.3389/fnana.2016.00123
  4. Gold BG, Nutt JG. Neuroimmunophilin ligands in the treatment of Parkinson’s disease. Curr Opin Pharmacol. 2002;2(1):82-86. https://doi.org/10.1016/S1471-4892(01)00125-4
  5. Ferreira J, Katzenschlager R, Bloem B, Bonuccelli U, Burn D, Deuschl G, Dietrichs E, Fabbrini G, Friedman A, Kanovsky P, Kostic V, Nieuwboer A, Odin P, Poewe W, Rascol O, Sampaio C, Schüpbach M, Tolosa E, Trenkwalder C, Schapira A, Berardelli A, Oertel WH. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease European. Journal of Neurology. 2013;20:5-15. https://doi.org/10.1111/j.1468-1331.2012.03866.x
  6. Cummings, J, Isaacson, S, Mills, R, Williams, H, Chi-Burris, K, Corbett A, Dhall R, Ballard C. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2013;383(9916):533-540. https://doi.org/10.1016/S0140-6736(13)62106-6
  7. Stayte S, Vissel B. Advances in non-dopaminergic treatments for Parkinson’s disease. Front Neurosci. 2014;8(22):113. https://doi.org/10.3389/fnins.2014.00113
  8. Galvez-Jimenez N, Fernandez HH, Espay AJ, Fox SH. Parkinson’s Disease: Current and Future Therapeutics and Clinical Trials. Cambridge University Press; 2016.
  9. Pilipovich AA, Golubev VL. The role of pronoran in the therapy of late stage of Parkinson’s disease. Zh Nevrol Psikhiatr Im. S.S. Korsakova. 2006;106(4): 34-37. (In Russ.) .
  10. Pogarell O, Gasser T, van Hilten JJ, Spieker S, Pollentier S, Meier D, Oertel WH. Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. Journal of Neurology Neurosurgery and Psychiatry. 2002;6(72):713-720. https://doi.org/10.1136/jnnp.72.6.713
  11. Rascol O, Brooks D, Korczyn A, De Deyn P, Clarke C, Lang A. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;20(342):1484-1491. https://doi.org/10.1056/nejm200005183422004
  12. Rinne U, Bracco F, Chouza C, Dupont E, Gershanik O, Masso JF M, Montastruc JL, Marsden CD. Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications: results of a double-blind levodopa controlled trial. Drugs. 1998;55(suppl 1):23-30. https://doi.org/10.2165/00003495-199855001-00004
  13. Grimes D, Gordon J, Snelgrove B, Lim-Carter I, Fon E, Martin W. Wieler M, Suchowersky O, Rajput A, Lafontaine AL, Stoessl J, Moro E, Schoffer K, Miyasaki J, Hobson D, Mahmoudi M, Fox S, Postuma R, Kumar H, Jog M. Canadian guidelines on Parkinson’s disease. Can J Neurol Sci. 2012;4(39):1-30.
  14. Pilipovich AA, Golubev VL. An impact of pronoran on cognitive and affective disorders in Parkinson’s disease. Zh Nevrol Psikhiatr Im. S.S. Korsakova. 2005;105(4):41-47. (In Russ.) .
  15. Grosset D, Antonini A, Caneci M, Pezzoli G, Lees A, Shaw K, Cubo E, Martinez-Martin P, Rascol O, Negre-Pages L, Senard A, Schwarz J, Strecker K, Reichmann H, Storch A, Löhle C, Stocchi F, Grosset K. Adherence to antiparkinson medication in a multicenter European study. Mov Disord. 2009;6(24):826-832. https://doi.org/10.1002/mds.22112
  16. Münchau A, Bhatia KP. Pharmacological treatment of Parkinson’s disease. Postgrad Med J. 2000;76(10):602-610.
  17. Maramai S, Gemma S, Brogi S, Campiani G, Butini S, Stark H, Brindisi M. Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases. Front Neurosci. 2016;10:451. https://doi.org/10.3389/fnins.2016.00451
  18. Frucht S, Rogers J, Greene P, Gordon M. F, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;9(52):1908-1908. https://doi.org/10.1212/wnl.52.9.1908
  19. Le Foll B, Collo G, Rabiner EA, Boileau I, Merlo Pich E, Sokoloff P. Dopamine D3 receptor ligands for drug addiction treatment: update on recent findings Prog. Brain Res. 2014;211:255-275. https://doi.org/10.1016/B978-0-444-63425-2.00011-8
  20. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002;2(303):791-804. https://doi.org/10.1124/jpet.102.039867
  21. Millan MJ. From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson’s disease. Pharmacol Ther. 2010;128(2):229-273. https://doi.org/10.1016/j.pharmthera.2010.06.002
  22. Jenner P. Parkinson’s disease: pathological mechanisms and actions of piribedil. J Neurol. 1992;239(suppl 1):2-8.
  23. Robertson HA, Peterson MR, Worth GG. Synergistic and persistent interaction between the D2 agonist, bromocriptine, and the D1 selective agonist, CY 208-243. Brain Res. 1992;593(2):332-334.
  24. Delaville C, Deurwaerdère PD, Benazzouz A. Noradrenaline and Parkinson’s disease. Front Syst Neurosci. 2011;5:31. https://doi.org/10.3389/fnsys.2011.00031
  25. Gobert A, Di Cara B, Cistarelli L, Millan MJ. Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors. J Pharmacol Exp Ther. 2003;305(1):338-346. https://doi.org/10.1124/jpet.102.046383
  26. Пилипович А.А. Биоэлектрическая активность головного мозга у пациентов с болезнью Паркинсона. Врач. 2012;4:107-112. Pilipovich AA. Bioelectrical activity of brain in patients with parkinson’s disease. Vrach. 2012;4:107-112. (In Russ.)].
  27. Calzi F, Bellasio R, Guiso G, Caccia S, Tacconi M.T. Effect of piribedil and its metabolite, S584, on brain lipid peroxidation in vitro and in vivo. Eur J Pharmacol. 1997;5(338):185-190. https://doi.org/10.1016/s0014-2999(97)81947-4
  28. Simon N, Micallef J, Reynier JC, Lesourd M, Witjas T, Alicherif A, Azulay JP, Blin O. End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson’s disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study. Mov Disord. 2005;7(20):803-809. https://doi.org/10.1002/mds.20400
  29. Smith L, De Salvia M, Jenner P, Marsden С. D. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Mov Disord. 1996;2(11):125-135. https://doi.org/10.1002/mds.870110203
  30. Watts RL. The role of dopamine agonists in early Parkinson’s disease. Neurology. 1997;1(suppl 1):49:34-48. https://doi.org/10.1212/wnl.49.1_suppl_1.s34
  31. Smith LA, Jackson MG, Bonhomme C, Chezaubernard C, Pearce RK, Jenner P. Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset. Clin Neuropharmacol. 2000;23(3):133-142.
  32. Montastruc JL, Ziegler M, Rascol O, Malbezin M. A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson’s disease. Mov Disord. 1999;14(2):336-341. https://doi.org/10.1002/1531-8257(199903)14:2<336::aid-mds1021>3.0.co;2-9
  33. Rascol O, Azulay JP, Blin O, Bonnet AM, Brefel-Courbon C, Césaro P, Damier P, Debilly B, Durif F, Galitzky M, Grouin JM, Pennaforte S, Villafane G, Yaici S, Agid Y. Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study. Mov Disord. 2010;25(3):368-376. https://doi.org/10.1002/mds.22922
  34. Sweet RD, Wasterlain CC, McDowell FH. Piribedil a dopamine agonist in Parkinson’s disease. Clin Pharmacol Ther. 1974;6(16):1077-1082.
  35. McLellan D, Chalmers R, Johnson R. Clinical and pharmacological evaluation of the effects of piribedil in patients with Parkinsonism. Acta neurol scand. 2009;1(51):74-82. https://doi.org/10.1111/j.1600-0404.1975.tb01360.x
  36. Perez-Lloret S, Rascol O. Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. CNS Drugs. 2016;30(8):703-717. https://doi.org/10.1007/s40263-016-0360-5
  37. Truelle J, Chanelet J, Bastard J, Six P, Emile J. Piribedil, dopaminergic agonist. Prolonged clinical and electrophysiological study in 60 parkinsonian patients. Nouv Presse Med. 1977;6(33):2987-2990.
  38. Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A. Early Piribedil Monotherapy of Parkinson’s Disease: A Planned Seven-Month Report of the REGAIN Study. Movement Disorders. 2006;12(21):2110-2115. https://doi.org/10.1002/mds.21122
  39. Rondot P, Ziegler M. Activity and acceptability of piribedil in Parkinson’s disease: a multicentre study. J Neurol. 1992;239:28-34.
  40. Callaghan N, Fitzpatrick G, O’Mahony J.В. Piribedil (ET 495) in the treatment of Parkinson’s disease combined with amantadine or levodopa. Acta Neurol Scand. 1975;3(52):179-186. https://doi.org/10.1111/j.1600-0404.1975.tb05772.x
  41. Ziegler M, Castro-Caldas A, Del Signore S, et al. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson’s disease: a 6-month, randomized, placebo-controlled study. Mov Disord. 2003;18:418-425.
  42. Salazar TG, Wix RR, Salazar AP, Jiménez León JC. The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson’s disease: a nine month follow up. Rev Neurol. 2004;38(8):715-719.
  43. Fedorova NV. Use of pronoran (piribedil) in Parkinson’s disease: the results of a multicenter study. Zh Nevrol Psikhiatr Im. S.S. Korsakova. 2003;103(11):21-24. (In Russ.) .
  44. Mentenopoulos G, Katsarou Z, Bostantjopoulou S, Logothetis J. Piribedil therapy in Parkinson’s diseases. Clin Neuropharmacol. 1989;12:23-28.
  45. Evidente VG, Esteban RP, Domingo FM, Carbajal LO, Parazo MA. Piribedil as an adjunct to levodopa in advanced Parkinson’s disease: the Asian experience. Parkinsonism Relat Disord. 2003;10(2):117-121.
  46. Suwantamee J, Nidhinandana S, Srisuwananukorn S, Laptikultham S, Pisarnpong A, Chankrachang S, Bundhukul A. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson’s disease: a 6-month open study. J Med Assoc Thai. 2004;87 (11):1293-1300.
  47. Rondot P, Bathien N, Dumas JL. Indications of piribedil in L-DOPA-treated parkinsonian patients: fysiopathologic implications. Adv Neurol. 1975;9:373-381.
  48. Tan EK, Ratnagopal P, Han SY, Wong MC. Piribedil and bromocriptine in Parkinson’s disease: a single-blind crossover study. Acta Neurol Scand. 2003;107(3):202-206. https://doi.org/10.1034/j.1600-0404.2003.02104.x
  49. Engel J, Granerus A, Savanborg A. Piribedil in Parkinson’s syndrome: a clinical study. Eur J Clin Pharmacol. 1975;2-3(8):223-226. https://doi.org/10.1007/bf00567119
  50. Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, Aguilar M, Del Signore S, Cesaro P. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson’s disease. Mov Disord. 2006;21(4):500-509. https://doi.org/10.1002/mds.20750
  51. Smith LA, Jackson MJ, Johnston L, Kuoppamaki M, Rose S, Al-Barghouthy G, Del Signore S, Jenner P. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates. Clin Neuropharmacol. 2006;29(3):112-125. https://doi.org/10.1097/01.WNF.0000220818.71231.DF
  52. Thobois S, Lhommée E, Klinger H, Ardouin C, Schmitt E, Bichon A, Kistner A, Castrioto A, Xie J, Fraix V, Pelissier P, Chabardes S, Mertens P, Quesada JL, Bosson JL, Pollak P, Broussolle E, Krack P. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain. 2013;5(136):1568-1577. https://doi.org/10.1093/brain/awt067
  53. Eggert K, Öhlwein C, Kassubek J, Wolz M, Kupsch A, Ceballos-Baumann A, Ehret R, Polzer U, Klostermann F, Schwarz J, Fuchs G, Jost W, Albert A, Haag A, Hermsen A, Lohmüller K, Kuhn K, Wangemann M, Oertel WH. Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole. Clin Neuropharmacol. 2014;37(4):116-122. https://doi.org/10.1097/WNF.0000000000000041
  54. Nagaraja D, Jayashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry. 2001;9(158):1517-1519. https://doi.org/10.1176/appi.ajp.158.9.1517
  55. Ollat H. Dopaminergic insufficiency reflecting cerebral ageing: value of a dopaminergic agonist, piribedil. J Neurol. 1992;239(suppl 1):13-16.
  56. Peretti CS, Gierski F, Harrois S. Cognitive skill learning in healthy older adults after 2 months of double-blind treatment with piribedil. Psychopharmacology. 2004;176(2):175-181. https://doi.org/10.1007/s00213-004-1869-8
  57. Schuck S, Bentue-Ferrer D, Kleinermans D, Reymann J.-M, Polard E, Gandon J-M, Allain H. Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers. Fundam Clin Pharmacol. 2002;16:57-65. https://doi.org/10.1046/j.1472-8206.2002.00070.x
  58. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic rewiew of prevalence studies of depression in Parkinson’s disease. Mov Disord. 2008;23:183-189. https://doi.org/10.1002/mds.21803
  59. Ring H A, Serra-Mestres J. Neuropsychiatry of the basal ganglia. Journal of Neurology Neurosurgery and Psychiatry. 2002;72:1221.
  60. Brocco M, Dekeyne A, Papp M, Millan MJ. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Behav Pharmacol. 2006;17(7):559-572. https://doi.org/10.1097/01.fbp.0000236267.41806.5b
  61. Schrag A, Sauerbier A, Chaudhuri KR. New clinical trials for nonmotor manifestations of Parkinson’s disease. Mov Disord. 2015;30(11):1490-1504. https://doi.org/10.1002/mds.26415
  62. Fedorova NV, Kim IP. Thetreatment of Parkinson disease. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2002;102(2):68-72. (In Russ.) .
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.